Abstract
Further study of FdCyd + THU is potentially warranted in urothelial carcinoma but not NSCLC or breast or H&N cancer. Increase in the proportion of p16-expressing cytokeratin-positive CTCs is a pharmacodynamic marker of FdCyd target engagement.
Introduction
Epigenetic silencing of tumor suppressor genes via DNA methylation is a hallmark of cancer progression. While DNA methyltransferase (DNMT) inhibitors like decitabine are approved for hematologic malignancies, their instability and toxicity have limited their utility in solid tumors. This study investigates 5-fluoro-2′-deoxycytidine (FdCyd), a more stable analog, administered with tetrahydrouridine (THU) to prevent metabolic degradation. A primary objective was to validate a novel "liquid biopsy" assay using circulating tumor cells (CTCs) to monitor real-time target engagement—specifically the reactivation of the silenced p16/INK4A gene.
Methods
This Phase 2 trial enrolled 95 patients across four strata: breast, head and neck (H&N), non-small cell lung (NSCLC), and urothelial cancer. Patients received IV FdCyd (100 mg/m²) and THU (350 mg/m²) for two weeks of a 28-day cycle.
To assess pharmacodynamics, the researchers modified the FDA-cleared CellSearch® system, adding a fifth fluorescence channel to detect p16 protein expression in CTCs. The assay distinguished between "classic" epithelial (Cytokeratin-positive) and mesenchymal-like (Vimentin-positive) CTCs.
Results
Clinical Efficacy and Survival
Clinical response was modest across most cohorts. However, the urothelial stratum showed a 4-month progression-free survival (PFS) rate of 42%, meeting the study's predefined threshold for further investigation. In contrast, breast, H&N, and NSCLC cohorts did not meet efficacy benchmarks.
Biomarker Validation and Target Engagement
The 5-channel CTC assay successfully demonstrated drug target engagement. Significant increases in p16-expressing CTCs were observed in 69% of evaluable patients, often as early as day 12 of the first treatment cycle.
Interestingly, mesenchymal-like (Vimentin-positive) CTCs were significantly more abundant than epithelial ones but appeared more resistant to p16 reactivation, suggesting these aggressive cell populations may require different therapeutic strategies.
Discussion
While the overall objective response rate was low, this study provides a critical "proof of concept" for using CTCs as a non-invasive pharmacodynamic marker for epigenetic therapies. The sensitivity observed in urothelial cancer suggests a potential role for FdCyd+THU in this population, perhaps as a priming agent for immunotherapy.
Major limitations included the high administration burden (ten 3-hour infusions per month) and the small number of patients with sufficient CTC counts for biomarker analysis. Future efforts are focusing on an oral formulation of FdCyd+THU to improve patient feasibility and enable broader clinical application.
Summary updated